EU reshapes HTAs: is the industry ready for it?
New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.
Regulation
Pfizer settles Biohaven kickback claims case for $59.7m
Atara’s T cell programmes hit with clinical hold after third-party site woes
Flu vaccine strategy on the line as new US leaders anticipated to take charge
Reprieve for Chinese biotechs as BIOSECURE Act left out of key bill
FDA shares new draft guidance for accelerated approval
FDA’s Marks says RFK Jr dialogue gives chance to have “lies debunked” on vaccines
BMS CFO backs “resilient” pharma industry amid RFK Jr’s impending governance
